|Mr. Steven B. Engle M.S.||CEO & Director||424.73k||N/A||1955|
|Dr. Pinchas Cohen||Co-Founder & Independent Director||64.12k||N/A||1957|
|Dr. Nir Yacov Barzilai||Co-Founder & Independent Director||64.12k||N/A||1956|
|Mr. Jeffrey F. Biunno CPA, M.B.A., CPA, MBA||CFO, Treasurer & Sec.||317.68k||35.05k||1966|
|Dr. Kenneth C. Cundy||Chief Scientific Officer||383.27k||26.03k||1959|
|Dr. David Andrew Sinclair A.O., Ph.D.||Co-Founder, Advisor & Consultant||N/A||N/A||1970|
|Ms. Jordyn Tarazi||Director of Investor Relations||N/A||N/A||N/A|
|Dr. Changhan David Lee Ph.D.||Consultant of Mitochondrial Biology||N/A||N/A||N/A|
|Dr. Rohit Loomba||Scientific Consultant||N/A||N/A||N/A|
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
CohBar, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 5; Compensation: 10.